Scotiabank initiated coverage of Vertex Pharmaceuticals (VRTX) with an Outperform rating and $495 price target
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Buy These 3 Stocks Now, Say Five-Star Analysts – November 11, 2025
- Vertex Pharmaceuticals: Hold Rating Amid High Valuation and Uncertain Growth Prospects Beyond Cystic Fibrosis
- Vertex Pharmaceuticals: Promising Growth in Renal Disease Market with Strong Clinical Data and Strategic Development
- Vertex Pharmaceuticals’ Promising Renal Franchise Developments Justify Buy Rating
- Cautious Optimism: Hold Rating on Vertex Pharmaceuticals Amid Promising Clinical Trial Data